Stada Arzneimittel

Last updated
STADA Arzneimittel AG
Company type Aktiengesellschaft
FWB:  SAZ
Industry Pharmaceuticals
Founded Dresden, 1895
Headquarters
Bad Vilbel
,
Germany
Key people
Peter Goldschmidt (CEO),

Simone Berger (CHRO), Miguel Pagan Fernandez (CTO), Boris Döbler (CFO),

Günter von Au (Chairman of the supervisory board)

Contents

Products Generic, over-the-counter drugs, Specialty Pharmaceuticals
Revenue€3.79 billion (2022) [1]
Number of employees
13,183 (FTE, as of December 31, 2022) [1]
Websitewww.stada.com

Stada Arzneimittel AG is a pharmaceutical company based in Bad Vilbel, Germany which specializes on a three-pillar strategy consisting of consumer healthcare products (over-the-counter drugs), generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In 2022, revenue totaled €3.79 billion. [2]

Commonly known products produced by Stada are Stada-brand acetaminophen and lactulose, Grippostad-C cold medicine and Ladival sun protection products. Stada is involved in various charity projects and sponsoring activities which include the support for dolphin aid e.V since 2007 and the support of a Romanian children's village in Timișoara.

History

Foundation & early history

Share of the Stada Arzneimittel AG, issued December 1970 Stada-Arzneimittel AG 1970.jpg
Share of the Stada Arzneimittel AG, issued December 1970

Stada was founded in Dresden in 1895 as a cooperative pharmacy. Stada was originally an acronym for Standardarzneimittel Deutscher Apotheker (Standard Drugs (of) German Pharmacists). After World War II, the company was relocated to Essen and Tübingen. In 1956 it was moved again to Bad Vilbel and in 1970, Stada began trading on the stock exchange as a public company. At that time the shares were restricted to pharmacists as restrictedly transferable registered shares. Five years later, Stada entered the generic drug market.

In 1999 Stada's German subsidiary, NIDDApharm GmbH, entered the German generic drugs market – worth an estimated 300 million DM. [3]

In September 2000, the company executed a 1:10 share split on the S-MAX. [4] In October the company entered into an agreement with Montenegro Group to acquire the pharmaceutical products of the "Bonomelli Farmacia" product line, rolling into the company's Italian subsidiary, EG S.p.A. – Laboratorie Eurogenerici. [5]

In July 2001 the company acquired the American generic drug supplier MOVA Laboratories Inc. [6]

In April 2002 the company acquired Spanish pharmaceutical company Bayvit S.A from Bayer and Vita S.A. Bayvit is the second-largest supplier of generic drugs in Spain, with recorded sales in 2000 of €20 million. [7] In May, the company acquired Marketing and Sales Operations of the Italian pharmaceutical company Crinos SpA, rolling it into the Italian subsidiary EG SpA. [8] In September the company established a joint venture in Brazil: Ava Stada Pharma Latin America Ltda, 51% owned by Stada and 49% owned by Brazilian company AVA Industrial S/A. [9] In November of the same year, the company acquired an increase shareholding in Ciclum Farma S.A., from 50% to 74%, with Grünenthal GmbH taking over the remaining 26% of shares. [10]

In January, 2003, the company announced its intention to acquire the majority interest in the Italian pharmaceutical company, Pharmajani SpA. Pharmajani specialises in the distribution of pharmacy products, expanding the company's operations and significantly strengthening the distribution capabilities of Stada's Italian subsidiaries, EG SpA and Crinos SpA. The company will change its name to New Pharmajani SpA (NPA). [11] In October the company acquired Schein Pharmaceutical Holdings UK Ltd and its subsidiary Schein Pharmaceutical UK Ltd from Schein Pharmaceutical (Bermuda) Ltd, a subsidiary of US-based Watson Pharmaceuticals, Inc. for €17 million. [12]

In August 2004 the company acquired 97.47% [13] of the shared of Nizhpharm OJSC for between €80.5 million. [14] [15]

In April 2005, the company acquired Portuguese generics supplier Ciclum Farma, Unipessoal LDA for €31 million. [16] In May, the company acquired the majority 58% stake in Chinese pharmaceuticals manufacturing company Beijing Center-Lab Pharmaceutical Company Ltd via its subsidiary Stada Pharmaceuticals (Asia) Ltd for €3.5 million. The deal will also strengthen Health Vision Enterprise Ltd, which is 51% owned by the company. [17]

In July 2006, the company sold US subsidiary Stada Inc. to Dava Pharmaceuticals Inc. for $40 million (€31 million). [18] Later in the same month, the company offered to acquire Serbian pharmaceutical group Hemofarm for €485 million (€146.97 per share) – marking Stada's largest acquisition to date. [19]

In August 2007 Stada's Russian subsidiary Nizhpharm OAO, acquired Makiz Group and its associated subsidiaries: Zzo Makiz-Pharma, Zzo Skopinpharm and Zzo Biodyne Pharmaceuticals for €125 million. [20] In the same month the company acquired Forum Bioscience Holdings Ltd for £37.7 million (€55.6 million). [21]

In November 2011, the company acquired the generics division of Spirig Pharma AG [22] for CHF 97 million (€78 million) [23]

In August 2013 the company completed the acquisition of UK-based over-the-counter manufacturer Thornton & Ross for £221.1 million (€259.2 million). [24]

In November 2016 Stada UK Holdings acquired Natures Aid, a manufacturer of vitamins, minerals, food supplements. [25]

Acquisition by Bain Capital & Cinven

In late 2016 into 2017, the company was approached by a number of potential acquirers. In February 2017, Boston private equity outfit Advent International made the first public and binding bid for the drugmaker, with a €58 per share in cash ($3.7 billion in total), in addition to a 2016 dividend payment. [26] In March 2017, it emerged that a number of other suitors had come to the fore; CVC Capital Partners – who helped the company dodge pressure from an activist investor in 2016 [27] in tandem with either China's Fosun Pharmaceutical or Shanghai Pharmaceuticals Holding. It also emerged that Mylan [28] and big pharma Merck & Co had been working with Credit Suisse on formulating a potential offer. [29]

In April 2017, it was reported that Bain Capital and Cinven tabled a bid valuing the company at about €5.3 billion (£4.5 billion). The private equity consortium offered €65.28 a share and a dividend of €0.72 per Stada share. [30] On June 27, 2017, Reuters reported that the Bain-Cinven bid to acquire the company had failed after only gaining 65.52% of shares. This was below the 67.5% minimum threshold needed to secure the acquisition. [31] In August 2017, Bain Capital and Cinven successfully acquired Stada Arzneimittel. [32]

Overview

The following is an illustration of the company's mergers, acquisitions, spin-offs and historical predecessors:

Stada Arzneimittel AG
NIDDApharm GmbH
Stada UK Holdings
Schein Pharmaceutical Holdings UK Ltd

Schein Pharmaceutical UK Ltd
(Acq 2003)

Forum Bioscience Holdings Ltd

Thornton & Ross
(Acq 2013)

Natures Aid
(Acq 2016)

EG S.p.A

Crinos SpA

Pharmajani SpA

Stada Inc.(Sold 2006)

MOVA Laboratories Inc.

Ava Stada Pharma Latin America Ltda

Bayvit S.A

Ciclum Farma, Unipessoal LDA

Nizhpharm OAO
MAKIZ Group

ZAO MAKIZ-Pharma

ZAO Skopinpharm

ZAO Biodyne Pharmaceuticals

Stada Pharmaceuticals (Asia) Ltd

Beijing Center-Lab Pharmaceutical Company Ltd

Health Vision Enterprise Ltd

Executive history

Matthias Widenfels resigned as chief executive officer (CEO) in January 2017 for "personal reasons"; he was replaced on an interim basis by Engelbert Coster Tjeenk Willink. [33] Claudio Albrecht became CEO in September 2017, shortly after the company's acquisition by Cinven and Bain Capital. [33] Peter Goldschmidt, head of Sandoz North America, will succeed Albrecht as CEO in September 2018, while Albrecht will remain with the company in a non-executive position. [33]

The company's supervisory board was at one time headed by Carl Ferdinand Oetker. By 2018, Günter von Au had taken this role. [33]

Related Research Articles

<span class="mw-page-title-main">Novartis</span> Swiss-American multinational pharmaceutical corporation

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.

The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and a presence in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany. The company is divided into three business lines: Healthcare, Life Sciences and Electronics. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies globally.

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.

<span class="mw-page-title-main">Gedeon Richter (company)</span> Hungarian pharmaceutical company

Gedeon Richter Plc. is a European multinational pharmaceutical and biotechnology company headquartered in Budapest. It is the largest pharmaceutical company in Central and Eastern Europe, with an expanding direct presence in Western Europe, China, Northern America and Latin America. Richter has the largest R&D unit in Central and Eastern Europe and operations in over 100 countries.

Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.

Cinven Limited is a global private equity firm founded in 1977, with offices in nine international locations in Guernsey, London, New York, Paris, Frankfurt, Milan, Luxembourg, Madrid, and Hong Kong that acquires Europe and United States based corporations, and emerging market firms that fit with their core businesses, and necessitate a minimum equity investment of €100 million or more. As of 2023, it has €39 billion in assets under management.

<span class="mw-page-title-main">Perrigo</span> Irish tax-registered pharmaceutical

Perrigo Company plc is an American Irish–registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.

<span class="mw-page-title-main">Hospira</span> American pharmaceutical company

Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It had approximately 19,000 employees. Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. It was formerly the hospital products division of Abbott Laboratories. On September 3, 2015, Hospira was acquired by Pfizer, who subsequently sold off the medical devices portion of Hospira to ICU Medical.

<span class="mw-page-title-main">Apotex</span> Canadian pharmaceutical company

Apotex Inc. is a Canadian pharmaceutical corporation. Founded in 1974 by Barry Sherman, the company is the largest producer of generic drugs in Canada, with annual sales exceeding CA$2.5 billion. By 2023, Apotex employed close to 8,000 people as Canada's largest drug manufacturer, with over 300 products selling in over 115 countries. Apotex manufactures and distributes generic medications for a range of diseases and health conditions that include cancer, diabetes, high cholesterol, glaucoma, infections and blood pressure.

<span class="mw-page-title-main">Teva Pharmaceuticals</span> Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals. Teva Pharmaceuticals was the largest generic drug manufacturer, when it was surpassed briefly by US-based Pfizer. Teva regained its market leader position once Pfizer spun off its generic drug division in a merger with Mylan, forming the new company Viatris at the end of 2020. Overall, Teva is the 18th largest pharmaceutical company in the world.

<span class="mw-page-title-main">Sun Pharma</span> Indian multinational pharmaceutical company

Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries across the globe. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Its active pharmaceutical products include baricitinib, brivaracetam, and dapaglifozin.

Hemofarm a.d., a member of STADA Group, is a Serbian pharmaceutical company based in Vršac, Serbia. Founded in 1960, it is one of the largest domestic producer and exporter of medicines in Serbia. Hemofarm currently operates in more than 30 countries on 3 continents and has around 3,000 employees.

<span class="mw-page-title-main">Sumitomo Pharma</span> Pharmaceutical company based in Japan

Sumitomo Pharma Co., Ltd. is a pharmaceutical company based in Japan. Its headquarters are in Chuo-ku, Osaka.

<span class="mw-page-title-main">Lupin Limited</span> Indian multinational pharmaceutical company

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

<span class="mw-page-title-main">Intas Pharmaceuticals</span> Indian multinational pharmaceutical company

Intas Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad. It is a producer of generic therapeutic drugs and engaged in contract clinical research and manufacturing. It has 18 manufacturing plants, 15 in India and the rest in United Kingdom and Mexico. In the financial year 2019, 69% of the company's revenue came from international markets while 31% came from India.

Amneal Pharmaceuticals, Inc. is an American publicly traded generics and specialty pharmaceutical company. The company is headquartered in Bridgewater, New Jersey.

<span class="mw-page-title-main">Piramal Group</span> Indian conglomerate

The Piramal Group is an Indian multinational conglomerate that has presence across various sectors such as healthcare, life sciences, drug discovery, financial services, alternative investment and real estate.

<span class="mw-page-title-main">Advanz Pharma</span>

Advanz Pharma Corp. is a British multinational pharmaceutical company headquartered in London. It changed its name from Concordia Healthcare Corp. in November 2018. The company focuses on a number of therapy areas including endocrinology, ophthalmology, urology, anti-infectives, pain management, central nervous system disorders, oncology, haematology, cardiology and intensive care medicine. The company also focuses on acquiring legacy pharmaceutical compounds which are usually off-patent. The operational headquarters is in London, UK, operations centre in Mumbai, India and regional hubs in Europe, Australia and Canada.

CSL Vifor is a global specialty pharmaceuticals company in the treatment areas of iron deficiency, dialysis, nephrology & rare disease. It is headquartered in Switzerland and consists of CSL Vifor, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Sanifit Therapeutics.

<span class="mw-page-title-main">Cheplapharm Arzneimittel</span>

Cheplapharm Arzneimittel GmbH, headquartered in Greifswald, is a German pharmaceutical company that markets branded drugs, medical products, supplements and cosmetics.

References

  1. 1 2 "Annual Report 2022" (PDF). Stada Arzneimittel. Retrieved 6 March 2023.
  2. ↑ name="AR2018"
  3. ↑ "Stada subsidiary NIDDApharm enters the German vaccine market" (Press release). Stada. 29 June 1999.[ self-published source ]
  4. ↑ "Stada Arzneimittel AG – Press Releases".
  5. ↑ "Stada Arzneimittel AG – Press Releases".
  6. ↑ "Stada Arzneimittel AG – Press Releases".
  7. ↑ "Stada Arzneimittel AG – Press Releases".
  8. ↑ "Stada Arzneimittel AG – Press Releases".
  9. ↑ "Stada Arzneimittel AG – Press Releases".
  10. ↑ "Stada Arzneimittel AG – Press Releases".
  11. ↑ "Stada Arzneimittel AG – Press Releases".
  12. ↑ "Stada Arzneimittel AG – Press Releases".
  13. ↑ "Stada Arzneimittel AG – Press Releases".
  14. ↑ "Stada Arzneimittel AG – Press Releases".
  15. ↑ "Stada Arzneimittel AG – Press Releases".
  16. ↑ "Stada Arzneimittel AG – Press Releases".
  17. ↑ "Stada Arzneimittel AG – Press Releases".
  18. ↑ "Stada Arzneimittel AG – Press Releases".
  19. ↑ "Stada Arzneimittel AG – Press Releases".
  20. ↑ "Stada Arzneimittel AG – Press Releases".
  21. ↑ "Stada Arzneimittel AG – Press Releases".
  22. ↑ "Stada Arzneimittel AG – Press Releases".
  23. ↑ "Stada Arzneimittel AG – Press Releases".
  24. ↑ "Arzneimittel AG – Press Releases".
  25. ↑ "Stada Arzneimittel AG – Press Releases".
  26. ↑ "Stada's first real bidder has put up a $3.7B offer. Will a bidding war follow? – FiercePharma".
  27. ↑ "Stada eyes €3.7B buyout to dodge activists' demands: WSJ – FiercePharma".
  28. ↑ "Is Mylan Stada's third suitor? One analyst thinks it may be – FiercePharma".
  29. ↑ "Merck (MRK) Said Planning to Join Bidding for Stada – Source".
  30. ↑ "Bain, Cinven pay up to win backing for Stada deal". 10 April 2017 – via uk.reuters.com.
  31. ↑ "Bain, Cinven discussing new offer for Stada – sources". 27 June 2017 – via uk.reuters.com.
  32. ↑ Manager-Magazin.de: Bain Capital und Cinven gelingt Kauf von Stada Arzneimittel (German)
  33. 1 2 3 4 Barber, Joe (1 February 2018). "Stada tabs Novartis executive to replace Claudio Albrecht as CEO" . FirstWord Pharma Plus. Doctor's Guide Publishing Limited. Retrieved 3 February 2018.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.